Mission Statement, Vision, & Core Values (2026) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.

Established in 1981 and traded as 600329.SS, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stands at the crossroads of tradition and modern healthcare, blending time-honored brands like Da Ren Tang, Long Shun Rong, Le Ren Tang and Ching Wan Hung with an integrated model of manufacturing, wholesale, retail and hospital management; the group's cultural depth is underscored by 5 National Intangible Cultural Heritage Projects and 12 Tianjin Intangible Cultural Heritage Projects, while its market scale is reflected in reported 7.31 billion CNY revenue in 2024 as it pursues a patient-first mission of "We Care. We Cure!", a vision "To Become a Market-driving and Technology-empowered Leader in the Healthcare Industry!" and core values of "Love With Honor and Power!" that drive investments in TCM modernization, tech-enabled R&D and expansion efforts that, as of December 2025, sustain its prominent role in China's healthcare landscape

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Intro

• Founded: 1981
• Business scope: Traditional Chinese Medicine (TCM) and Western pharmaceuticals - manufacturing, wholesale distribution, retail operations, hospital management services
• Heritage brands: Da Ren Tang, Long Shun Rong, Le Ren Tang, Ching Wan Hung
• Honors: 5 National Intangible Cultural Heritage Projects; 12 Tianjin Intangible Cultural Heritage Projects
• 2024 revenue: 7.31 billion CNY
• Stock code: 600329.SS

• Preserve and modernize traditional Chinese medicine while ensuring high-quality, safe pharmaceutical products for patients and consumers.
• Integrate research, manufacturing, and clinical application to deliver evidence-based TCM and complementary Western therapies.
• Promote sustainable operations across supply chains and healthcare services to improve community health outcomes.

• To be a leading national and internationally respected integrated healthcare group that bridges TCM heritage with modern medical science.
• Drive innovation in product development, digital healthcare, and integrated hospital services to expand patient access and treatment effectiveness.

• Heritage & Respect - safeguard traditional knowledge and cultural assets while adapting them to contemporary needs.
• Quality & Safety - prioritize rigorous quality control across manufacturing and distribution.
• Innovation & Evidence - invest in R&D and clinical validation that integrates TCM and Western medicine.
• Service & Accessibility - strengthen retail and hospital networks to ensure broad patient access.
• Responsibility & Sustainability - uphold ethical practices, regulatory compliance, and community engagement.

• Strengthen R&D pipelines to increase proportion of proprietary and clinically validated TCM products.
• Optimize integrated supply chain and retail/hospital channels to improve gross margin and working capital efficiency.
• Leverage brand heritage and intangible assets for premium positioning and licensing opportunities.
• Pursue digital transformation across e-commerce, telemedicine, and hospital information systems to capture higher patient lifetime value.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Overview

Mission Statement - 'We Care. We Cure!'

• The phrase foregrounds patient-centric care: prioritizing safety, accessibility and compassionate service across manufacturing, distribution and clinical support.
• 'Care' emphasizes holistic wellbeing and preventive approaches rooted in a long-standing tradition of traditional Chinese medicine (TCM) combined with modern clinical practices.
• 'Cure' signals commitment to delivering effective therapeutic products spanning TCM formulations, modern pharmaceuticals and health supplements to address acute and chronic conditions.
• The mission reflects continuity: the company's strategic decisions, R&D prioritization and product portfolio evolution consistently align with this dual focus on care and cure.

How the mission translates into measurable activity

• Product portfolio alignment: sustained investment in TCM heritage products while expanding chemically-synthesized and biotech lines to improve clinical efficacy and broaden therapeutic coverage.
• Patient-centric operations: quality systems, post-market pharmacovigilance and community health initiatives designed to improve patient outcomes and trust.
• Integration of traditional and modern medicine: clinical research programs and collaborations with hospitals and academic institutions to validate and modernize TCM therapies.

Core values and strategic priorities

• Patient first - safety, efficacy, and accessibility.
• Integrity - regulatory compliance and transparent reporting.
• Innovation - advancing R&D in both TCM standardization and modern drug development.
• Sustainability - responsible manufacturing and supply chain resilience.
• Collaboration - partnerships with clinical, research and distribution networks to scale impact.

Selected quantitative indicators (most recent reported annual figures)

Operational levers supporting the mission

• Quality & compliance: GMP-certified manufacturing sites and continuous improvement in pharmacovigilance.
• Clinical validation: randomized trials and real-world evidence programs to demonstrate efficacy of integrated TCM-modern therapies.
• Supply chain resilience: vertical integration and multi-source procurement to secure active ingredients and minimize disruption.
• Commercial strategy: diversified channels (hospital, retail pharmacy, e-commerce) to ensure patient access.

Strategic outcomes tied to 'We Care. We Cure!'

• Improved product safety metrics and reduced adverse-event incidence through enhanced monitoring.
• Portfolio modernization with incremental launches of standardized TCM formulations meeting contemporary clinical guidelines.
• Revenue and profitability growth driven by higher-margin modern medicines and expanded service offerings.
• Strengthened brand trust in domestic markets and measured international expansion aligning with quality standards.

Further reading: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited: History, Ownership, Mission, How It Works & Makes Money

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Mission Statement

• 'Market-driving' denotes proactive product strategy: anticipating consumer-health trends, shaping demand through clinical evidence and brand-building, and leveraging distribution partnerships to expand reach.
• 'Technology-empowered' highlights investments in digital R&D platforms, GMP automation, and data-driven quality control to shorten product development cycles and improve margins.
• The vision underpins strategic moves to modernize TCM formulations, pursue biopharmaceutical integrations, and target export growth in ASEAN, MENA, and other overseas markets.

• R&D modernization - integrate AI-assisted discovery, standardized herbal extraction technologies, and clinical trial capabilities to validate efficacy and safety.
• Manufacturing upgrade - expand GMP-certified production lines, implement Industry 4.0 automation, and tighten supply-chain traceability.
• Market expansion - strengthen hospital channels, retail pharmacy penetration, cross-border e-commerce, and international regulatory filings.
• Brand & quality assurance - elevate scientific communication, post-market surveillance, and digital patient engagement to build trust.

• CapEx allocation: prioritize automated production lines and quality-control labs to reduce unit costs and improve throughput.
• R&D roadmap: increase clinical trial portfolio for key TCM proprietary products and register two to three product dossiers in target overseas markets annually.
• Digital transformation: deploy ERP, MES, and a pharmacovigilance platform to shorten time-to-market and improve compliance.
• Strategic partnerships: seek co-development with biotech firms and cross-border distributors to accelerate global market entry.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Vision Statement

• 'Love With Honor and Power!' - a guiding phrase that shapes culture and strategy.
• Love: patient-centered care and compassionate stakeholder engagement.
• Honor: uncompromising ethical standards, regulatory compliance, and reputational stewardship.
• Power: ambition to scale market leadership through innovation, strategic partnerships, and operational excellence.

• Elevate quality and safety across product lines, especially in traditional Chinese medicine (TCM) and modern pharmaceuticals.
• Increase R&D investment to convert TCM heritage into clinically validated therapies.
• Expand domestic and international distribution channels to enhance accessibility and brand influence.
• Strengthen corporate governance and ESG practices to reinforce Honor and build long-term stakeholder trust.

• Quality KPIs: batch release compliance >99%, product recall rate <0.1% annually.
• Ethics & compliance: full regulatory audit coverage and supplier code-of-conduct enforcement.
• Innovation metrics: pipeline molecules/formulations in clinical/preclinical stages and patents filed annually.
• Social impact: community health programs, patient assistance initiatives, and workforce wellbeing metrics.